Review Papers Claim by Claim

Visual review — Déry et al., MCB 2008 (DOI:10.1128/mcb.02025-07)

Concise evidence map (text)

• Conserved GAR motif & methylation: MRE11 GAR contains ≥9 arginines across vertebrates; MRE11 purified from Sf9 is methylated and interacts with PRMT1 — methylation blocked by MTA/ADOX Déry et al., GAR methylation and PRMT1 interaction
• Biochemical mechanism: First six arginines (RI) critical: R→A or R→K substitutions in RI reduce exonuclease and alter DNA binding; paradoxically these mutants show stronger endonuclease activity and aggregation on ssDNA by EM — suggests GAR tunes DNA engagement mode and local concentration on DNA Déry et al., GAR mutants alter nuclease balance
• GAR is a DNA-binding module and methylation enhances binding: ΔGAR reduces DNA binding and exonuclease; GAR fragment from Sf9 (methylated) binds DNA more strongly than bacterially produced unmethylated GAR Déry et al., GAR binds and methylation enhances binding
• Cellular relevance: Methylation inhibition (ADOX) reduces MRE11 and RAD51 recruitment to an I-SceI-induced single DSB (to ~31% and ~19% of control respectively); GFP-GAR-NLS is sufficient to form γ-H2AX-colocalizing foci; FRAP shows methylation alters chromatin retention (GAR-WT t1/2 ~486 ms vs GAR-RA ~379 ms) Déry et al., in vivo localization and FRAP

Critical appraisal — strengths and limitations

Context with later work

• MRN complex architecture and Rad50–Mre11 mechanistic models (structural work, e.g., Mre11/Rad50 structures) provide a framework that supports how altered DNA binding domains (like GAR) could change processing outcomes by changing local engagement (see structural MR literature) MR structural framework (Cell 2001)
• Recent reviews and functional studies show MRN regulation is multi-layered (post-translational modifications, CtIP, Nbs1 effects) and that nuclease contributions differ across organisms; Déry et al. added an arginine-methylation dimension that fits into a broader regulatory map of MRE11 function and recruitment MRN review (Cancers 2022)

Where could this paper mislead or overreach?

1. Inhibitor experiments using global methylation inhibitors are suggestive but not definitive that MRE11 methylation alone controls in vivo RAD51 foci — inhibition could impair other factors required for HR.
2. Overexpressed GAR fusions forming foci demonstrates sufficiency but not necessity under endogenous expression levels; ΔGAR effects in endogenous MRE11 knock-in models would be decisive and were not shown.
3. Interpretation that methylation occurs prior to MRN assembly is logical from co-IP in insect cells but needs demonstration in human cells at endogenous expression; competing explanations (e.g., transient interactions) remain possible.

What experiments would decisively strengthen or falsify the core claims?

1. Create CRISPR knock-in human cell lines that replace endogenous MRE11 GAR arginines (RI) with R→K and R→A and assay: (a) quantitative resection kinetics (BrdU/ssDNA assays), (b) RAD51 loading, (c) sensitivity to IR and Top2 poisons, and (d) chromatin fractionation of endogenous MRN—this tests physiological necessity and rules out overexpression/inhibitor artifacts.
2. Use site-specific proteomics (LC-MS/MS) to map methylation stoichiometry at each arginine in the GAR region in unstressed vs damaged cells and after PRMT1 knockdown; coupling to mutational rescue (PRMT1 KO + methyl-mimic) would clarify dynamics and dependency.
3. In vitro single-molecule DNA curtains or smFRET with WT vs RI mutants to measure DNA-binding dwell time, processivity, and nuclease cleavage site selection — this would directly connect GAR-mediated binding dynamics to exonuclease vs endonuclease outcomes.

Conclusions (evidence-weighted)